Companies › Regeneron Pharmaceuticals
53 active drug programs in 287 registered trials: 131 Phase 2, 74 Phase 1, 55 Phase 3, 27 Phase 4; Oncology, Metabolic and endocrine, Immunology, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| dupilumab Interleukin-4 receptor subunit alpha antagonist | IL4R | Phase 4 | Asthma; Chronic Obstructive Pulmonary Disease (COPD); Atopic Dermatitis; Eosinophilic Esophagitis (EoE) … | Nov 2026 |
| Linvoseltamab anti-B-cell maturation antigen x anti-CD3 bispecific antibody | BCMA, GPRC5D, CD3E, TNFRSF17 | Phase 4 | Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) … | Aug 2027 |
| Pozelimab Complement C5 inhibitor | C5 | Phase 4 | CHAPLE Disease; Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia Gravis … | Jul 2028 |
| Aflibercept Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 3 | Neovascular Age-Related Macular Degeneration; Diabetic Maculopathy; Diabetic Macular Edema (DME); Proliferative Diabetic Retinopathy (PDR) … | Jan 2027 |
| REGN7508 Factor XI inhibitor | F11 | Phase 3 | Venous Thromboembolism (VTE); Symptomatic Venous Thromboembolism (VTE); Atrial Fibrillation (AF); Peripheral Artery Disease (PAD) … | Feb 2027 |
| REGN9933 Factor XI inhibitor | F11 | Phase 3 | Atrial Fibrillation (AF); Venous Thromboembolism (VTE); Peripheral Artery Disease (PAD); End-Stage Kidney Disease (ESKD) | Feb 2027 |
| Cemiplimab (REGN2810) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Melanoma; Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma (CSCC); Advanced Non-Small Cell Lung Cancer … | Mar 2027 |
| Fianlimab (REGN3767) Lymphocyte activation gene 3 protein inhibitor | LAG3 | Phase 3 | Melanoma; Advanced Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Resectable Non-small Cell Lung Cancer … | Mar 2027 |
| Mibavademab Leptin receptor agonist | LEPR | Phase 3 | Monogenic Obesity; Generalized Lipodystrophy; Functional Hypothalamic Amenorrhea | Jun 2027 |
| ALN-CIDEB CIDEB inhibitor | CIDEB | Phase 3 | Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Aug 2027 |
| Odronextamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma … | Feb 2028 |
| Cemdisiran Complement C5 mRNA RNAi inhibitor | C5 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia Gravis | Jul 2028 |
| Garetosmab Inhibin beta A chain inhibitor | INHBA | Phase 3 | Fibrodysplasia Ossificans Progressiva; Obesity | Feb 2029 |
| Carfilzomib 26S proteasome inhibitor | PSMD1, PSMB2, PSMB1, PSMB5, PSMB8 | Phase 3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | May 2029 |
| Freneslerbart Fel d 1 monoclonal antibody | – | Phase 3 | Allergic Conjunctivitis | May 2029 |
| Mevonlerbart Fel d 1 monoclonal antibody | – | Phase 3 | Allergic Conjunctivitis | May 2029 |
| REGN-2Cat Dual Fel d 1 monoclonal antibody combination | – | Phase 3 | Allergic Conjunctivitis | May 2029 |
| Olatorepatide (HS-20094) GLP-1 and GIP receptor agonist | GLP1R, GIPR | Phase 2 | Overweight or Obesity | Nov 2026 |
| REGN7999 Antibody targeting iron homeostasis in non-transfusion dependent β-thalassemia | – | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Dec 2026 |
| ALN-ANG3 ANGPTL3 inhibitor | ANGPTL3 | Phase 2 | Diabetic Kidney Disease (DKD); Healthy Volunteers With Hyperlipidemia | Dec 2026 |
| Alirocumab Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 2 | Hypercholesterolemia; Dyslipidemias; Early PCSK9 Inhibitor on Ventricular Remodling; Acute Myocardial Infarction … | Dec 2026 |
| Ubamatamab Anti-MUC16 monoclonal antibody | MUCIN16 | Phase 2 | Ovarian Cancer; Non Small Cell Lung Cancer; Recurrent Ovarian Cancer; SMARCB1-Deficient Malignancies | May 2027 |
| ALN-PNP PNPLA3 inhibitor (reduces Patatin-like phospholipase domain-containing protein 3 expressio | PNPLA3 | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD); Healthy Volunteers | Aug 2027 |
| BNT116 personalized neoantigen vaccine | – | Phase 2 | Advanced Non-Small Cell Lung Cancer | Jan 2028 |
| REGN13335 | – | Phase 2 | Pulmonary Arterial Hypertension (PAH) | Feb 2028 |
| ALN-HSD HSD17B13 inhibitor via RNA interference (gene silencing) | HSD17B13 | Phase 2 | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | Apr 2028 |
| REGN10597 PD-1-IL2Ra-IL2 immunotherapy | PDCD1, IL2RA, IL2 | Phase 2 | Ovarian Cancer; Non Small Cell Lung Cancer; Melanoma | Jun 2028 |
| Marlotamig Unclear mechanism - code-named REGN7075 | – | Phase 2 | Non Small Cell Lung Cancer | Dec 2029 |
| Trevogrumab GDF8 (myostatin) inhibitor | MSTN | Phase 2 | Obesity | – |
| REGN7075 OX40 (TNFRSF4) agonist antibody | TNFRSF4 | Phase 1 | Advanced Solid Tumors | Nov 2026 |
| REGN22044 | – | Phase 1 | Healthy Volunteer | Feb 2027 |
| REGN20934 GLP-1 receptor agonist | – | Phase 1 | Overweight or Obesity | Feb 2027 |
| REGN9533 Monoclonal antibody targeting anticoagulation pathway in hemodialysis | – | Phase 1 | End-Stage Kidney Disease (ESKD) | Apr 2027 |
| 89Zr-DFO-REGN5054 Zirconium-89 labeled immunoPET imaging agent targeting PD-L1 | – | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| REGN5093 (davutamig) MET inhibitor | MET | Phase 1 | NSCLC | Jul 2027 |
| REGN5678 Anti-NECTIN4 antibody | NECTIN4 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Castration-resistant Prostate Cancer | Nov 2027 |
| REGN20423 | – | Phase 1 | Healthy Volunteer | Aug 2028 |
| REGN5668 | – | Phase 1 | Ovarian Cancer | Nov 2028 |
| REGN5837 | – | Phase 1 | B-cell Non-Hodgkins Lymphoma (B-NHL) | Feb 2029 |
| DB-OTO AAV-mediated otoferlin gene delivery | OTOF | Phase 1 | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Feb 2029 |
| ALN-SNCA SNCA mRNA inhibitor (siRNA) | SNCA | Phase 1 | Parkinsons Disease | Jun 2029 |
| Vonsetamig (REGN5459) CD28 costimulation modulator bispecific antibody | CD28 | Phase 1 | Lupus Nephritis (LN) | Sep 2029 |
| REGN22530 Protein antagonist that blocks fluid accumulation in the eye to reduce intraocular pressur | – | Phase 1 | Primary Open Angle Glaucoma (POAG) | Sep 2029 |
| ALN-CFB small interfering RNA (siRNA) targeting Complement Factor B | CFB | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Nov 2029 |
| BPX-601 Anti-PSCA CAR-T cell therapy | PSCA | Phase 1 | Prostate Cancer | Feb 2030 |
| REGN4336 CD3-engaging bispecific antibody with PSMA-targeting domain | – | Phase 1 | Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Mar 2030 |
| 27T51 MUC16-targeting CAR T cell therapy | MUC16 | Phase 1 | Epithelial Ovarian Cancer | May 2030 |
| REGN15505 4-1BB (TNFRSF9) agonist with PSMA-targeting domain | – | Phase 1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Oct 2030 |
| REGN17235 unclear - SF3B1-directed therapy | – | Phase 1 | Clonal Cytopenia of Undetermined Significance (CCUS) | May 2031 |
| ALN-SOD SOD1 mRNA inhibitor (RNAi therapeutic) | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis (ALS) | Mar 2032 |
| REGN17372 | – | Phase 1 | Relapsed Refractory Multiple Myeloma (RRMM) | Sep 2033 |
| REGN7945 B cell maturation antigen (BCMA) targeting agent; mechanism not fully disclosed in registr | – | Phase 1 | Relapsed/Refractory Multiple Myeloma | Nov 2033 |
| REGV131-LNP1265 Coagulation Factor IX gene insertion therapy delivered via LNP | F9 | Phase 1 | Hemophilia B | Aug 2034 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03480568 | Alirocumab | Phase 3 | Hemodialysis | Cardiovascular | Aug 2020 |
| NCT04632433 | Cemiplimab (REGN2810) | Phase 2 | Cutaneous Squamous Cell Carcinoma | Oncology | Feb 2023 |
| NCT05537948 | Alirocumab | Phase 4 | Dyslipidemias | Metabolic and endocrine | Jan 2024 |
| NCT05401786 | Cemiplimab (REGN2810) | Phase 2 | Carcinoma, Non-Small-Cell Lung | Oncology | Nov 2024 |
| NCT05285839 | dupilumab | Phase 4 | Atopic Dermatitis | Immunology | Dec 2024 |
| NCT05001984 | Alirocumab | Phase 2 | Intracranial Atherosclerosis | Cardiovascular | Apr 2025 |
| NCT04430179 | dupilumab | Phase 2 | Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis | Respiratory | Jul 2025 |
| NCT05553834 | Cemiplimab (REGN2810) | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Sep 2025 |
| NCT05553834 | Alirocumab | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Sep 2025 |
| NCT04731155 | Alirocumab | Phase 4 | Early PCSK9 Inhibitor on Ventricular Remodling | Other | Oct 2025 |
| NCT06850571 | Aflibercept | Phase 4 | Diabetic Maculopathy | Metabolic and endocrine | Dec 2025 |
| NCT06750471 | dupilumab | Phase 4 | Nasal Polyps | Respiratory | Dec 2025 |
| NCT05942222 | dupilumab | Phase 4 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Apr 2026 |
| NCT06299098 | Trevogrumab | Phase 2 | Obesity | Metabolic and endocrine | Jun 2026 |
| NCT06299098 | Garetosmab | Phase 2 | Obesity | Metabolic and endocrine | Jun 2026 |
| NCT05133531 | Pozelimab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Sep 2026 |
| NCT05133531 | Cemdisiran | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | Hematology | Sep 2026 |
| NCT05574101 | Cemiplimab (REGN2810) | Phase 2 | Cutaneous Squamous Cell Carcinoma | Oncology | Oct 2026 |
| NCT02612454 | dupilumab | Phase 3 | Atopic Dermatitis | Immunology | Oct 2026 |
| NCT07431086 | Olatorepatide (HS-20094) | Phase 2 | Overweight or Obesity | Metabolic and endocrine | Nov 2026 |
| NCT04626635 | REGN7075 | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2026 |
| NCT06665971 | dupilumab | Phase 4 | Eosinophilic Esophagitis (EoE) | Immunology | Nov 2026 |
| NCT03951831 | Cemiplimab (REGN2810) | Phase 2 | Prostate Cancer Metastatic | Oncology | Nov 2026 |
| NCT05831176 | dupilumab | Phase 2 | Eosinophilic Gastritis (EoG) | Gastroenterology | Nov 2026 |
| NCT06088771 | Cemiplimab (REGN2810) | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06088771 | dupilumab | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06421636 | REGN7999 | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Hematology | Dec 2026 |
| NCT06452771 | ALN-ANG3 | Phase 1 | Healthy Volunteers With Hyperlipidemia | Metabolic and endocrine | Dec 2026 |
| NCT04989946 | Fianlimab (REGN3767) | Phase 1 | Prostate Cancer | Oncology | Dec 2026 |
| NCT06623656 | Cemiplimab (REGN2810) | Phase 2 | Carcinoma, Non-Small-Cell Lung | Oncology | Dec 2026 |
| NCT04989946 | Cemiplimab (REGN2810) | Phase 1 | Prostate Cancer | Oncology | Dec 2026 |
| NCT06352073 | dupilumab | Phase 4 | Eosinophilic Esophagitis | Gastroenterology | Dec 2026 |
| NCT05268107 | dupilumab | Phase 4 | Atopic Dermatitis | Immunology | Dec 2026 |
| NCT05292404 | Alirocumab | Phase 4 | Acute Myocardial Infarction | Cardiovascular | Dec 2026 |
| NCT07477704 | Alirocumab | Phase 2 | Hypercholesterolemia | Metabolic and endocrine | Dec 2026 |
| NCT06477653 | dupilumab | Phase 2 | Hypereosinophilic Syndrome | Hematology | Dec 2026 |
| NCT04862650 | Cemiplimab (REGN2810) | Phase 2 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oncology | Dec 2026 |
| NCT04315701 | Cemiplimab (REGN2810) | Phase 2 | Recurrent Skin Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06004986 | dupilumab | Phase 4 | Atopic Dermatitis | Immunology | Dec 2026 |
| NCT04380038 | dupilumab | Phase 4 | Asthma | Respiratory | Dec 2026 |
| NCT05094570 | dupilumab | Phase 4 | Nasal Polyps | Infectious disease | Dec 2026 |
| NCT05347771 | dupilumab | Phase 2 | Asthma | Respiratory | Dec 2026 |
| NCT04781322 | Alirocumab | Phase 1 | Alcohol Associated Liver Disease | Immunology | Dec 2026 |
| NCT05535738 | dupilumab | Phase 2 | Skin Inflammation | Immunology | Jan 2027 |
| NCT07128641 | Odronextamab | Phase 2 | Follicular Lymphoma | Oncology | Jan 2027 |
| NCT06491914 | Aflibercept | Phase 3 | Neovascular Age-Related Macular Degeneration | Ophthalmology | Jan 2027 |
| NCT03694158 | dupilumab | Phase 4 | Asthma | Respiratory | Jan 2027 |
| NCT02298959 | Aflibercept | Phase 1 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Oncology | Jan 2027 |
| NCT06860815 | Cemiplimab (REGN2810) | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Jan 2027 |
| NCT04600362 | dupilumab | Phase 2 | Nummular Eczema | Immunology | Jan 2027 |
| NCT07526116 | REGN22044 | Phase 1 | Healthy Volunteer | Other | Feb 2027 |
| NCT07175428 | REGN7508 | Phase 2 | Atrial Fibrillation (AF) | Cardiovascular | Feb 2027 |
| NCT07175428 | REGN9933 | Phase 2 | Atrial Fibrillation (AF) | Cardiovascular | Feb 2027 |
| NCT07015905 | REGN7508 | Phase 3 | Venous Thromboembolism (VTE) | Cardiovascular | Feb 2027 |
| NCT07594093 | REGN20934 | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Feb 2027 |
| NCT06705387 | dupilumab | Phase 2 | Eosinophilic Esophagitis | Gastroenterology | Mar 2027 |
| NCT06246916 | Fianlimab (REGN3767) | Phase 3 | Melanoma | Oncology | Mar 2027 |
| NCT06246916 | Cemiplimab (REGN2810) | Phase 3 | Melanoma | Oncology | Mar 2027 |
| NCT04387084 | Cemiplimab (REGN2810) | Phase 1 | Advanced Malignant Skin Neoplasm | Oncology | Mar 2027 |
| NCT07759167 | REGN7508 | Phase 1 | End-Stage Kidney Disease (ESKD) | Genitourinary | Apr 2027 |
The 60 nearest readouts of 287 trials; the rest in the app.
Cash and short-term investments of $9.3bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
PDCD1 (2) CD3E (2) C5 (2) F11 (2) LAG3 (1) GLP1R (1) GIPR (1) MS4A1 (1) CD3G (1) CD3D (1) BCMA (1) GPRC5D (1)
Johnson & Johnson (Janssen) AstraZeneca Roche Eli Lilly Akeso Novo Nordisk Innovent Biologics (Suzhou) Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Amgen
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.